CG Oncology Accelerates Bladder Cancer Trial Results by Nearly a Year
CG Oncology announces earlier-than-expected results for its Phase 3 bladder cancer trial, moving timeline up by nearly one year due to rapid patient enrollment.
/ 1661 items
#XY↓
uniQure Moves Forward with Huntington's Disease Treatment
uniQure secures FDA meeting to discuss accelerated approval for AMT-130, bringing hope to the Huntington's disease community with potentially life-changing gene therapy.
Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug Approval
Aquestive Therapeutics stock plunges after FDA identifies deficiencies in Anaphylm application, a sublingual film treatment for severe allergic reactions.
Citizens Upgrades Allogene Therapeutics to Outperform
Citizens upgraded Allogene Therapeutics to Outperform with a $5 target, citing improved trial visibility and strong long-term sales potential for cema-cel.
Ardelyx Surges as Analysts Boost Targets on Strong Ibsrela Outlook
Ardelyx shares jumped after strong Ibsrela guidance, multiple analyst upgrades, higher price targets, and a faster path to $1B in revenue.
Tilray Brands Reports Narrower Q2 Loss Despite Mixed Sales Performance
Tilray (TLRY) narrows Q2 losses to $43.5M with 3% revenue growth driven by cannabis gains, though beverage sales decline 21% amid international expansion strategy.